Case report: CAR-T therapy demonstrated safety and efficacy in relapsed/refractory diffuse large B-cell lymphoma patients complicated with hepatitis B-related cirrhosis
2024

CAR-T Therapy for Lymphoma Patients with Liver Cirrhosis

Sample size: 3 publication 10 minutes Evidence: moderate

Author Information

Author(s): Kong Danqing, Ping Nana, Zhu Qian, Zhang Xiao, Li Junhong, Zou Rui, Wu Depei, Jin Zhengming, Qu Changju

Primary Institution: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Hypothesis

Can CAR-T therapy be safely and effectively used in DLBCL patients with hepatitis B-related cirrhosis?

Conclusion

CAR-T therapy is effective for treating DLBCL patients with HBV-related cirrhosis, but requires careful monitoring for liver complications.

Supporting Evidence

  • All three patients achieved complete remission after CAR-T therapy.
  • The progression-free survival rate was 100% after a median follow-up of 42 months.
  • Patients experienced complications related to cirrhosis, including HBV reactivation.

Takeaway

Doctors used a special treatment called CAR-T therapy to help three patients with a type of blood cancer and liver problems, and it worked well for them.

Methodology

Three patients with relapsed/refractory DLBCL and HBV-related cirrhosis were treated with CAR-T therapy and monitored for outcomes and complications.

Potential Biases

Potential bias due to the small sample size and retrospective nature of the study.

Limitations

The study includes a small number of cases and lacks long-term follow-up data.

Participant Demographics

Two male and one female patient, aged 46 to 62 years.

Digital Object Identifier (DOI)

10.3389/fonc.2024.1491100

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication